Apparent loss of 5hmC in tumours can occur through loss-of-function mutations in TET enzymes that oxidise 5mC to 5hmC, or inhibition of TET activity by the oncometabolite beta-hydroxyglutarate generated by mutant IDH1/2. This evidence concerns the gene IDH1 and neoplasm.